Automated Device for Asthma Monitoring and Management in Monitoring Adult Patients With Lung Cancer Undergoing Radiation Therapy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03340714 |
Recruitment Status :
Active, not recruiting
First Posted : November 13, 2017
Last Update Posted : December 1, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lung Carcinoma | Device: Monitoring Device | Not Applicable |
PRIMARY OBJECTIVES:
I. Determine compliance with the Automated Device for Asthma Monitoring and Management (ADAMM) device in patients receiving radiation therapy (RT) for lung cancer.
SECONDARY OBJECTIVES:
I. Evaluate feasibility of recruitment, acceptability of the ADAMM device, and compliance with electronic patient-reported outcomes (ePROs) in this patient population
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 24 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | A Pilot Study Investigating the Feasibility of ADAMM (Automated Device for Asthma Monitoring and Management) in Combination With Electronic Patient-Reported Outcomes in Adult Patients With Lung Cancer |
Actual Study Start Date : | March 20, 2018 |
Actual Primary Completion Date : | October 25, 2021 |
Estimated Study Completion Date : | March 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Device Feasibility (ADAMM)
Patients wear the Automated Device for Asthma Monitoring and Management (ADAMM) from the time of computed tomography (CT) simulation for radiation therapy (RT) planning throughout the entire RT course and for 4 weeks post-RT
|
Device: Monitoring Device
Wear ADAMM |
- Percentage of hours per day that patients wear the Automated Device for Asthma Monitoring and Management device [ Time Frame: Up to 4 weeks post-radiation therapy ]The compliance rate along with a one-sided exact 95% confidence interval will be estimated.
- Percentage of days per study period that patients wear the Automated Device for Asthma Monitoring and Management device [ Time Frame: Up to 4 weeks post-radiation therapy ]The compliance rate along with a one-sided exact 95% confidence interval will be estimated.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients are capable of giving informed consent
- Patients are eligible to be treated with RT and plan to start treatment
- Patients have either metastatic or non-metastatic lung cancer as defined in history and physical
- Patients must be able to read or speak English
- Women of reproductive potential should have a negative serum or urine pregnancy test within one week prior to radiation planning CT scan
Exclusion Criteria:
- Patients who cannot read or speak English
- Patients who are not candidates for RT treatment
- Women of childbearing potential who are pregnant or breastfeeding

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03340714
United States, Pennsylvania | |
Sidney Kimmel Cancer Center at Thomas Jefferson University | |
Philadelphia, Pennsylvania, United States, 19107 |
Principal Investigator: | Maria Werner-Wasik, MD | Sidney Kimmel Cancer Center at Thomas Jefferson University |
Responsible Party: | Sidney Kimmel Cancer Center at Thomas Jefferson University |
ClinicalTrials.gov Identifier: | NCT03340714 |
Other Study ID Numbers: |
17P.209 |
First Posted: | November 13, 2017 Key Record Dates |
Last Update Posted: | December 1, 2022 |
Last Verified: | November 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | Yes |
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases |